Uta Oelschlagel
Dresden, SN, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 65 publications
Teclistamab interference with anti-BCMA chimeric antigen receptor T-cell detection by flow cytometry: duration and clinical implications.
Journal: Leukemia
Published: October 16, 2025
Measurable residual disease by multicolor flow cytometry in acute myeloid leukemia: A comparison of peripheral blood and bone marrow.
Journal: Cytometry. Part B, Clinical cytometry
Published: September 18, 2025
Independent confirmation of the immunophenotypic ELN Scoring System in patients with MDS and CMML.
Journal: HemaSphere
Published: September 05, 2025
Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial.
Journal: The Lancet. Haematology
Published: September 01, 2025
Prognostic Value of Multicolor-Flow Cytometric Measurable Residual Disease Detection in Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation: Potential Role of HLA-DR.
Journal: Clinical lymphoma, myeloma & leukemia
Published: July 02, 2025
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA Trial.
Journal: American journal of hematology
Published: June 25, 2025
Inflammatory Mesenchymal Stromal Cells and IFN-responsive T cells are key mediators of human bone marrow niche remodeling in CHIP and MDS.
Journal: bioRxiv : the preprint server for biology
Published: December 09, 2024
Prognostic value of flow cytometry in myelodysplastic neoplasms (MDS): Composition of a FCM-prognostic score (FCM-PS) for overall survival.
Journal: HemaSphere
Published: December 01, 2024
Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.
Journal: HemaSphere
Published: January 31, 2024
Last Updated: 09/26/2026